Anti-Inflammatory Therapeutics Global Market Report 2024

The global anti-inflammatory therapeutics market has grown steadily in recent years. It will grow from $109.88 billion in 2023 to $114.71 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to prevalence of chronic diseases, aging population, increased awareness, and government initiatives.

The global anti-inflammatory therapeutics market is expected to see steady growth in the next few years. It will grow to $135.6 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to innovative therapies, increasing healthcare expenditure, focus on rare diseases, biologics and biosimilars. Major trends in the forecast period include advancements in immunotherapy, artificial intelligence (AI) and machine learning (ML) in drug discovery, expansion of indications.

The growing incidence of inflammatory bowel disease is set to drive the expansion of the anti-inflammatory therapeutics market. Inflammatory bowel disease (IBD) is a chronic condition characterized by inflammation in the gastrointestinal tract. Anti-inflammatory therapeutics play a pivotal role in the treatment of conditions like Crohn's disease, as they help reduce inflammation, manage symptoms, and lower the likelihood of surgery. For example, a July 2023 report from Oxford University Press (OUP), the university press of the University of Oxford, indicates that IBD has an incidence of 10.9 per 100,000 person-years and a prevalence of 721 per 100,000 people. Consequently, the rising prevalence of inflammatory bowel disease is a significant driver of growth in the anti-inflammatory therapeutics market.

The rising incidence of drug-related side effects poses a challenge and may impede the growth of the market in the foreseeable future. Anti-inflammatory therapeutics like ibuprofen can lead to side effects due to the intricate nature of inflammatory signaling pathways and the potential for exacerbating inflammation under specific circumstances. For example, as of August 2022, according to Drugs.com, a US-based online drug reference, approximately 4% to 16% of individuals using ibuprofen tablets reported experiencing at least one gastrointestinal side effect. Hence, the increasing occurrence of drug side effects is a factor restraining the growth of the anti-inflammatory therapeutics market in the coming years.

The increasing prevalence of autoimmune disorders is expected to drive the expansion of the anti-inflammatory therapeutics market in the future. Autoimmune disorders encompass a group of medical conditions where the body's immune system, typically responsible for defending against harmful invaders like bacteria and viruses, erroneously targets and attacks the body's own healthy cells and tissues. The growing prevalence of autoimmune disorders plays a significant role in the increasing demand for anti-inflammatory therapeutics. These therapeutics are frequently employed in the treatment of autoimmune disorders, aiming to reduce inflammation, regulate the overactive immune response, and alleviate the symptoms associated with these conditions. For instance, as reported in January 2022 by the Guardian Media Group, a UK-based media company, it is anticipated that there will be 4 million people in the UK suffering from autoimmune disorders, with a global increase estimated at 3% to 9% annually. Additionally, data from May 2023 from the University of Oxford, a UK-based research university, indicates that autoimmune disorders affect 10% of the world's population. Consequently, the rising prevalence of autoimmune disorders is a driving force behind the growth of the anti-inflammatory therapeutics market.

Prominent companies within the anti-inflammatory therapeutics market are actively introducing innovative drugs as a strategy to enhance their market presence. As an example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based pharmaceutical and healthcare company, jointly introduced Kevzara (sarilumab). This represents the first and only anti-inflammatory biologic designed for adult patients dealing with polymyalgia rheumatic (PMR), an inflammatory rheumatic condition. It is particularly targeted at individuals who either do not respond adequately to corticosteroids or cannot tolerate corticosteroid tapering.

In March 2022, Pfizer Inc., a US-based biopharmaceutical company, completed a $6.7 billion acquisition of Arena Pharmaceuticals. This strategic move by Pfizer is intended to enhance its portfolio in the field of inflammation and immunology therapeutics, with a focus on conditions such as ulcerative colitis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. Arena Pharmaceuticals, a US-based company, specializes in the development of diverse anti-inflammatory drugs for the treatment of various immuno-inflammatory disorders.

Major players in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-inflammatory therapeutics market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-inflammatory therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drug classes used in anti-inflammatory therapeutics encompass nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anti-inflammatory biologics. Nonsteroidal anti-inflammatory drugs are analgesic medications without opioids that are commonly employed by individuals to alleviate mild physical discomfort. These medications find diverse applications in conditions like arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel diseases, and more. They are available through a range of distribution channels, including retail pharmacies, hospital pharmacies, and online retail platforms.

This report provides anti-inflammatory therapeutics market statistics, including anti-inflammatory therapeutics industry global market size, regional shares, competitors with an anti-inflammatory therapeutics market share, detailed anti-inflammatory therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the anti-inflammatory therapeutics industry. These anti-inflammatory therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-inflammatory therapeutics market consists of sales of Ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.